Pharmacotherapy and prevention of vascular dementia

CNS and Neurological Disorders - Drug Targets

Volumn 10, Issue 3, 2011, Pages 370-390

  Moretti, A ^a   Gorini, A ^a   Villa, R F ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Alzheimer's disease; Dementia; Prevention; Therapy; Vascular dementia

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; CANDESARTAN; DIHYDROERGOTOXINE MESILATE; DONEPEZIL; ENALAPRIL MALEATE PLUS NITRENDIPINE; FENOFIBRATE; GALANTAMINE; GINKGO BILOBA EXTRACT; HYDROCHLOROTHIAZIDE; INDAPAMIDE PLUS PERINDOPRIL; INSULIN; MEMANTINE; NAFTIDROFURYL; NICARDIPINE; NICERGOLINE; NIMODIPINE; NITRENDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; NOOTROPIC AGENT; PENTOXIFYLLINE; PERINDOPRIL; PIRACETAM; PITAVASTATIN; PLACEBO; PROPENTOFYLLINE; RIVASTIGMINE; ROSIGLITAZONE; SIBUTRAMINE; UNINDEXED DRUG;

ALZHEIMER DISEASE; ARTICLE; CADASIL; COMORBIDITY; DYSLIPIDEMIA; GINKGO BILOBA; HUMAN; HYPERTENSION; INFLAMMATION; LOW DRUG DOSE; METABOLIC SYNDROME X; MULTIINFARCT DEMENTIA; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PHARMACOGENOMICS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

EID: 79951718638     PISSN: 18715273     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152711794653832     Document Type: Article

References (293)

1. Loeb, C. Vascular dementia. Dementia, 1990, 1, 175-184.
2. Román, G.C. Vascular dementia: distinguishing characteristics, treatment and prevention. J. Am. Geriatr. Soc., 2003, 51, 1-9.
3. Bowler, J.V.; Hachinski, V., Eds.; Vascular Cognitive Impairment: Preventable Dementia. Oxford University Press: Oxford, 2003, pp. 1-337.
4. Aggarwal, N.T.; DeCarli, C. Vascular dementia: emerging trends. Semin. Neurol., 2007, 27, 66-77.
5. Jellinger, K.A. Morphological diagnosis of vascular dementia-A critical update. J. Neurol. Sci., 2008, 270, 1-12.
6. Martinez-Vila, E; Murie-Fernández, M.; Gállego Perez-Larraya, J.; Irimia, P. Neuroprotection in vascular dementia. Cerebrovasc. Dis., 2006, 21(Suppl. 2), 106-117.
7. Erkinijuntti, T.; Román, G.; Gauthier, S.; Feldman, H.; Rockwood, K. Emerging therapies for vascular dementia and vascular cognitive impairment. Stroke, 2004, 35, 1010-1017.
8. Pantoni, L.; Poggesi, A.; Inzitari, D. The relation between whitematter lesions and cognition. Curr. Opin. Neurol., 2007, 20, 390-397.
9. Erkinijuntti, T. Subcortical vascular dementia. Cerebrovasc. Dis., 2002, 13(Suppl. 2), 58-60.
10. Oliva, A.; Mani, R.; Katz, R. Regulatory aspects of vascular dementia in the United States. Int. Psychogeriatr., 2003, 15(Suppl 1), 293-295.
11. Lopez, O.L.; Kuller, L.H.; Becker, J.T. Diagnosis, risk factors, and treatment of vascular dementia. Curr. Neurol. Neurosci. Rep., 2004, 4, 358-367.
12. O'Brien, J.T.; Erkinijuntti, T.; Reiseberg, B.; Roman, G.; Sawada, T.; Pantoni, L.; Bowler, J.V.; Ballard, C.; DeCarli, C.; Gorelick, P.B.; Rockwood, K.; Burns, A.; Gauthier, S.; DeKosky, S.T.; Vascular cognitive impairment. Lancet Neurol., 2003, 2, 89-98.
13. Ward, N.S.; Brown M.M. In: Cerebral Blood Flow and Metabolism in Vascular Dementia. Vascular Cognitive Impairment. Preventable Dementia, Bowler, J.V.; Hachinski, V, Eds.; Oxford University Press: Oxford, 2003; pp. 193-207.
14. Shuff, N.; Matsumoto S.N.; Kmiecik, J.; Studholme, C.; Du, A.; Ezekiel, F.; Miller, B.L.; Kramer, J.H.; Jagust, W.J.; Chui, H.C.; Weiner, M.W. Cerebral blood flow in ischemic vascular dementia and Alzheimer's disease, measured by arterial spin-labeling magnetic resonance imaging. Alzheimer's Dement., 2009, 5, 454-462.
15. De Reuck, J.; Decoo, D.; Hasenbroekx, M.C.; Lamont, B.; Santens, P.; Goethals, P.; Strijckmans, K.; Lemahieu, I. Acetazolamide vasoreactivity in vascular dementia: a positron emission tomography study. Eur. Neurol., 1999, 41, 31-36.
16. Schuff, N.; Capizzano, A.A.; Du, AT.; Amend, D.L.; O'Neill, J.; Norman, D.; Jagust, W.J.; Chui, H.C.; Kramer, J.H.; Reed, B.R.; Miller, B.L.; Yaffe, K.; Weiner, M.W. Different patterns of Nacetylaspartate loss in subcortical ischemic vascular dementia and AD. Neurology, 2003, 61, 358-364.
17. Sachdef, P.F.; Looi, J.C. In: Neuropsychological Differentiation of Alzheimer's Disease and Vascular Dementia. Vascular Cognitive Impairment. Preventable Dementia, Bowler, J.V.; Hachinski, V, Eds.; Oxford University Press: Oxford, 2003; pp. 153-175.
18. Kerrouche, N.; Herholz, K.; Mielke, R.; Holthoff, V.; Baron, J.-C. 18FDG PET in vascular dementia: differentiation from Alzheimer's disease using voxel-based multivariare analysis. J Cerebr. Flow Metab., 2006, 26, 1213-1221.
19. Bäckman, L.; Small, B.J. Cognitive deficits in preclinical Alzheimer's disease and vascular dementia: patterns of findings from the Kungsholmen Project. Physiol. Behav., 2007, 92, 80-86.
20. Bugiani, O. Aβ-related cerebral amyloid angiopathy. Neurol. Sci., 2004, 25, S1-S2.
21. Román, G.C.; Kalaria, R.N. Vascular determinants of cholinergic deficits in Alzheimer disease and vascular dementia. Neurobiol. Aging, 2006, 27, 1769-1785.
22. Tohgi, H.; Abe, T.; Kimura, M.; Saheki, M.; Takahashi, S. Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer-type dementia. J. Neural Transm., 1996, 103, 1211-1220.
23. Wallin, A.; Sjögren, M.; Blennow, K.; Davidsson, P. Decreased cerebrovascular fluid acetylcholinesterase in patients with subcortical ischemic vascular dementia. Dement. Geriatr. Cogn. Disord., 2003, 16, 200-207.
24. Gottfries, C.G.; Blennow, K.; Karlsson, I.; Wallin, A. The neurochemistry of vascular dementia. Dementia, 1994, 5, 163-167.
25. Sakurada, T.; Alufuzoff, I.; Winblad, B.; Nordberg, A. Substance P-like immunoreactivity, choline acetyltransferase activity and cholinergic muscarinic receptors in Azheimer' disease and multiinfarct dementia. Brain Res., 1990, 521, 329-332.
26. Perry, E.; Ziabreva, I.; Perry, R.; Aarsland, D.; Ballard, C. Absence of cholinergic deficits in "pure" vascular dementia. Neurology, 2005, 64, 132-133.
27. Pimlott, S.L.; Piggott, M.; Owens, J.; Greally, E.; Court, J.A.; Jaros, E.; Perry, R.H.; Perry, E.K.; Wyper, D. Nicotinic acetylcholine receptor distribution in Alzheimer's disease, dementia with Lewy bodies, Parkinson's disease, and vascular dementia: in vitro binding study using 5-[125I]-A-85380. Neuropsychopharmacology, 2004, 29, 108-116.
28. Tomimoto, H.; Ohtani, R.; Shibata, M.; Nakamura, N.; Ihara, M. Loss of cholinergic pathways in vascular dementia of the Binswanger type. Dement. Geriatr. Cogn. Disord., 2005, 19, 282-288.
29. Kimura, S.; Saito, H.; Minami, M.; Togashi, H.; Nakamura, N.; Nemoto, M.; Parvez, H.S. Pathogenesis of vascular dementia in stroke-prone spontaneously hypertensive rats. Toxicology, 2000, 153, 167-178.
30. Francis, P.T.; Palmer, A.M.; Snape, M.; Wilcock, G.K. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J. Neurol. Neurosurg. Psychiatry, 1999, 66, 137-147.
31. Bartus, R.T. On neurodegenerative diseases, models and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp. Neurol., 2000, 163, 495-529.
32. Amenta, F.; Parnetti, L.; Gallai, V.; Wallin, A. Treatment of cognitive dysfunction associated with Alzheimer's disease with cholinergic precursors: ineffective treatments or inappropriate approaches? Mech. Ageing Dev., 2001, 122, 2025-2040.
33. Amenta, F.; Di Tullio, M.A.; Tomassoni, D. The cholinergic approach for the treatment of vascular dementia: evidence from pre-clinical and clinical studies. Clin. Exp. Hypertens., 2002, 24, 697-713.
34. Parnetti, L.; Mignini, F.; Tomassoni, D.; Traini, E.; Amenta, F. Cholinergic precursors in the treatment of cognitive impairment of vascular origin: ineffective approaches or need for re-evaluation? J. Neurol. Sci., 2007, 257, 264-269.
35. Fioravanti, M.; Yanagi, M. Cytidinediphosphocholine (CDPcholine) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst. Rev., 2005, 2, CD000269.
36. Farlow, M.R. Use of antidementia agents in vascular dementia: beyond Alzheimer disease. Mayo Clin. Proc., 2006, 81, 1350-1358.
37. Lojkowska, W.; Ryglewicz, D.; Jedrzejczak, T.; Minc, S.; Jakubowska, T.; Jarosz, H.; Bochynska, A. The effect of cholinesterase inhibitors on the regional blood flow in patients with Alzheimer's disease and vascular dementia. J. Neurol. Sci., 2003, 216, 119-126.
38. Román, G.C.; Wilkinson, D.G.; Doody, R.S.; Black, S.E.; Salloway, S.P.; Schindler, R.J. Donepezil in vascular dementia: combined analysis of two large-scale clinical trials. Dement. Geriatr. Cogn. Disord., 2005, 20, 338-344.
39. Dichgans, M.; Markus, H.S.; Salloway, S.; Verkkoniemi, A.; Moline, M.; Wang, Q.; Poster, H.; Chabriat, H.S. Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL. Lancet Neurol., 2008, 7, 310-318.
40. Erkinjuntti, T.; Kurz, A.; Gauthier, S.; Bullock, R.; Lilienfeld, S.; Damaraju, C.V. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet, 2002, 359, 1283-1290.
41. Auchus, A.P.; Brashear, H.R.; Salloway, S.; Korczyn, A.D.; De Deyn, P.P., Gassmann-Mayer, C. Galantamine treatment of vascular dementia. Neurology, 2007, 69, 448-458.
42. Ballard, C.; Sauter, M.; Scheltens, P.; He, Y.; Barkhof, F.; van Straaten, E.C.W.; van der Flier, W.M.; Hsu, C.; Wu, S.; Lane, R. Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the Vantage study. Curr. Med. Res. Opin., 2008, 24, 2561-2574.
43. Kavirajan, H.; Schneider, L.S. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol., 2007, 6, 782-792.
44. Moretti, R.; Torre, P.; Antonello, R.M.; Cazzato, G.; Pizzolato, G. Different responses to rivastigmine in subcortical vascular dementia and multi-infarct dementia. Am. J. Alzheimer's Dis. Other Dement., 2008, 23, 167-177.
45. Kuhl, D.E.; Minoshima, S.; Frey, K.A.; Foster, N.L.; Kilbourn, M.R.; Koeppe, R.A. Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex. Ann. Neurol., 2000, 48, 391-395.
46. Zhao, Q.; Tang, X.C. Effects of huperzine A on acetylcholinesterase isoforms in vitro: comparison with tacrine, donepezil, rivastigmine and physostigmine. Eur. J. Pharmacol., 2002, 455, 101-107.
47. Davis, B.; Sadik, K. Circadian cholinergic rhythms: implications for cholinesterase inhibitor therapy. Dement. Geriatr. Cogn. Disord., 2006, 21, 120-129.
48. Pepeu, G.; Giovannini, M.G. Cholinesterase inhibitors and beyond. Curr. Alzheimer Res., 2009, 6, 86-96.
49. Maggini, M.; Vanacore, N.; Raschetti, R. Cholinesterase inhibitors: drugs looking for a disease? PLoS Med., 2006, 3, 40.
50. Korczyn, A.D. Drugs for vascular dementia. Lancet Neurol., 2007, 6, 749-751.
51. Rammes, G.; Danysz, W.; Parsons, C.G. Pharmacodynamics of memantine: an update. Curr. Neuropharmacol., 2008, 6, 55-78.
52. Benzi, G.; Gorini, A.; Arnaboldi, R.; Ghigini, B.; Villa, R.F. Agerelated alterations by chronic intermittent hypoxia on cerebral synaptosomal ATPase activities. J. Neural Transm., 1994, 44, 159-171.
53. Villa, R.F.; Gorini, A.; Hoyer, S. ATP-ases of synaptic plasma membranes from hippocampus after ischemia and recovery during ageing. Neurochem. Res., 2002, 27, 861-870.
54. Villa, R.F.; Gorini, A.; Hoyer, S.; Effect of ageing and ischemia on enzymatic actitivites linked to Krebs' cycle, electron transfer chain, glutamate and aminoacids metabolism of free and intrasynaptic mithocondria of cerebral cortex. Neurochem. Res., 2009, 34, 2102-2116.
55. Creeley, C.; Wozniak, D.F.; Labruyere, J.; Taylor, G.T.; Olney, J.W. Low doses of memantine disrupt memory in adult rats. J. Neurosci., 2006, 26, 3923-3932.
56. Drever, B.D.; Anderson, W.G.L.; Johnson, H.; O'Callaghan, M.; Seo, S.; Choi, D-Y.; Riedel, G.; Platt, B. Memantine acts as cholinergic stimulant in the mouse hippocampus. J. Alzheimer Dis., 2007, 12, 319-333.
57. Maskell, P.D.; Speder, P.; Newberry, N.R.; Bermudez, I. Inhibition of human a7 nicotinic acetylcholine receptors by open channel blockers of N-methyl-D-aspartate receptors. Br. J. Pharmacol., 2003, 140, 1313-1319.
58. Orgogozo, J.M.; Rigaud, A.S.; Stöffler, A.; Möbius, H.J.; Forette, F. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke, 2002, 33, 1834-1839.
59. Wilcock, G.; Möbius, H.J.; Stöffler, A. A double-blind, placebocontrolled multicentre study of memantine in mild to moderate vascular dementia (MMM 500). Int. Clin. Psychopharmacol., 2002, 17, 297-305.
60. McShane, R.; Areosa Sastre, A.; Minakaran, N. Memantine for dementia. Cochrane Database Syst. Rev., 2006, 2, CD003154.
61. Nagasawa, H.; Kogure, K.; Kawashima, K.; Ido, T.; Itoh, M.; Hatazawa, J. Effects of co-dergocrine mesylate (Hydergine) in multi-infarct dementia as evaluated by positron emission tomography. Tohoku J. Exp. Med., 1990, 162, 225-233.
62. Schneider, L.S.; Olin, J.T. Overview of clinical trials of Hydergine in dementia. Arch. Neurol., 1994, 51, 787-798.
63. Olin, J.; Schneider, L.; Novit, A.; Luczak, S. Hydergine for dementia. Cochrane Database Syst. Rev., 2001, 2, CD000359.
64. Villa, R.F. Effect of hypoxia on the cerebral energy state. Il Farmaco Ed. Sci., 1975, 30, 561-567.
65. Moretti, A. Metabolic and neurochemical effects of nicergoline on the central nervous system: a review of the experimental studies (in German). Arzneim.-Forsch. Drug Res., 1979, 29, 1213-1223.
66. Le Poncin-Lafitte, M.; Grosdemouge, C.; Duterte, D.; Rapin, J.R. Simultaneous study of haemodynamic, metabolic and behavioural sequelae in a model of cerebral ischaemia in aged rats: effects of nicergoline. Gerontology, 1984, 30, 109-119.
67. Moretti, A.; Carfagna, N.; Caccia, C.; Carpentieri, M. Effect of ergolines on neurotransmitter systems in the rat brain. Arch. Int. Pharmacodyn. Thér., 1988, 294, 33-45.
68. Ogawa, N.; Asanuma, M.; Hirata, H.; Kondo, Y.; Kawada, Y.; Mori, A. Cholinergic deficits in aged rat brain are corrected with nicergoline. Arch. Gerontol. Geriatr., 1993, 16, 103-110.
69. Pogliani, E.; della Volpe, A.; Ferrari, R.; Recalcati, P.; Praga, C. Inhibition of human platelet aggregation by oral administration of nicergoline: a double-blind study. Farmaco Prat., 1975, 30, 630-640.
70. Saletu, B.; Paulus, E.; Linzmayer, L.; Anderer, P.; Semlitsch, H.V.; Grünberger, J.; Wicke, L.; Neuhold, A.; Podreka, I. Nicergoline in senile dementia of Alzheimer type and multi-infarct dementia: a double-blind, placebo-controlled, clinical and EEG/ERP mapping study. Psychopharmacology, 1995, 117, 385-395.
71. Herrmann, W.H.; Stephan, K.; Gaede, K.; Apeceche, M. A multicenter randomized double-blind study on the efficacy and safety of nicergoline in patients with multi-infarct dementia. Dement. Geriatr. Cogn. Disord., 1997, 8, 9-17.
72. Fioravanti, M.; Flicker, L. Effect of nicergoline in dementia and other age associated forms of cognitive impairment. Cochrane Database Syst. Rev., 2001, 4, CD003159.
73. Winblad, B.; Fioravanti, M.; Dolezal, T.; Logina, I.; Milanov, I.G.; Popescu, D.C.; Solomon, A. Therapeutic use of nicergoline. Clin. Drug Investig., 2008, 28, 533-552.
74. Meneses, A.; Terrón, J.A.; Ibarra, M.; Hong, E. Effects of nimodipine on learning in normotensive and spontaneously hypertensive rats. Behav. Brain Res., 1997, 85, 121-125.
75. Scriabine, A.; van den Kerckhoff, W. Pharmacology of nimodipine: a review. Ann. NY. Acad. Sci., 1988, 522, 698-706.
76. Tomassoni, D.; Lanari, A.; Silvestrelli, G.; Traini, E.; Amenta, F. Nimodipine and its use in cerebrovascular disease: evidence from recent preclinical and controlled clinical studies. Clin. Exp. Hypertens., 2008, 30, 744-766.
77. Lopez-Arrieta, J.M.; Birks, J. Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst. Rev., 2002, 1, CD000147.
78. Pantoni, L.; del Ser, T.; Soglian, A.G.; Amigoni, S.; Spadari, G.; Binelli, D.; Inzitari, D. Efficacy and safety of nimodipine in subcortical vascular dementia: a randomized placebo-controlled trial. Stroke, 2005, 36, 619-624.
79. Amenta, F.; Tomassoni, D.; Traini, E.; Mignini, F.; Veglio, F. Nicardipine: a hypotensive dihydropyridine-type calcium antagonist with a peculiar cerebrovascular profile. Clin. Exp. Hypertens., 2008, 30, 808-826.
80. Spanish Group of Nicardipine Study in Vascular Dementia. An experimental, randomized, double-blind, placebo-controlled clinical trial to investigate the effect of nicardipine on cognitive function in patients with vascular dementia (in Spanish). Rev. Neurol., 1999, 28, 835-845.
81. González-González, J.A.; Lozano, R. A study of the tolerability and effectiveness of nicardipine retard in cognitive deterioration of vascular origin (in Spanish). Rev. Neurol., 2000, 30, 719-728.
82. Hartmann, A. Comparative randomized study of cerebral blood flow after long-term administration of pentoxifylline and codergocrine mesylate in patients with chronic cerebrovascular disease. Curr. Med. Res. Opin., 1985, 9, 475-479.
83. Müller, R.; Lehrach, F. Haemorheology and cerebrovascular disease: multifunctional approach with pentoxifylline. Curr. Med. Res. Opin., 1981, 7, 253-263.
84. Sha, M.C.; Callahan, C.M. The efficacy of pentoxifylline in the treatment of vascular dementia: a systematic review. Alzheimer Dis. Assoc. Disord., 2003, 17, 46-54.
85. Parkinson, F.E.; Rudolphi, K.A.; Fredholm, B.B. Propentofylline: a nucleoside transport inhibitor with neuroprotective effects in cerebral ischemia. Gen. Pharmacol., 1994, 25, 1053-1058.
86. Sasaki, M.; Naritomi, H.; Kanashiro, M.; Nishimura, H.; Sawada, T. Effects of propentofylline on energy metabolism of the ischemic brain studied by in vivo 31P nuclear magnetic resonance spectroscopy. Arzneim. Forsch. Drug Res., 1989, 39, 886-889.
87. Plaschke, K.; Martin, E.; Bardenheuer, H.J. Effect of propentofylline on hippocampal brain energy state and amyloid precursor protein concentration in a rat model of cerebral hypoperfusion. J. Neural. Transm., 1998, 105, 1065-1077.
88. Goto, M.; Demura, N.; Sakaguchi, T. Effects of propentofylline on disorder of learning and memory in rodents. Jpn. J. Pharmacol., 1987, 45, 373-378.
89. Mielke, R.; Kittner, B.; Ghaemi, M.; Kessler, J.; Szelies, B., Herholz, K.; Heiss, W.D. Propentofylline improves regional cerebral glucose metabolism and neuropsychological performance in vascular dementia. J. Neurol. Sci., 1996, 141, 59-64.
90. Kittner, B. Clinical trials of propentofylline in vascular dementia. Alzheimer Dis. Assoc. Dis., 1999, 13(Suppl. 3), S166-S171.
91. Frampton, M.; Harvey, R.J.; Kirchner, V. Propentofylline for dementia. Cochrane Database Syst. Rev., 2003, 2, CD002853.
92. Maloteaux, J.M.; Halech, J.; De Campeneere, D.; Berta, P.; Vidal, N. Biochemical and physiological evidence for antiserotoninergic properties of naftidrofuryl. Arzneim. Forsch. Drug Res., 1986, 36, 1194-1198.
93. Kirsten, R.; Erdeg, B.; Moxter, D.; Hesse, K.; Breidert, M.; Nelson, K. Platelet aggregation after naftidrofuryl application in vitro and ex vivo. Int. J. Clin. Pharmacol. Ther., 1995, 33, 81-84.
94. Krieglstein, J.; Sauer, D.; Nuglisch, J.; Rossberg, C.; Beck, T.; Bielenberg, G.W.; Mennel, H.D. Nafidrofuriyl protects neurons against ischemic damage. Eur. Neurol., 1989, 29, 224-228.
95. Lamproglou, Y.; Le Poncin, M.; Jacques, W.; Wiernsperger, N.; Rapin, J.R. Postischemic breakdown in hippocampal protein synthesis and mnesic deficits in rats: pharmacological improvement by curative naftidrofuryl treatment. Metab. Brain Dis., 1992, 7, 165-174.
96. Emeriau, J.P.; Lehert, P.; Mosnier, M. Efficacy of naftidrofuryl in patients with vascular or mixed dementia: results of a multicenter, double-blind trial. Clin. Ther., 2000, 22, 834-844.
97. Hoyer, S.; Lannert, H.; Nöldner, M.; Chatterjee, S.S. Damaged neuronal energy metabolism and behavior are improved by Ginkgo biloba extract (EGb 761). J. Neural Transm., 1999, 106, 1171-1188.
98. Sastre, J.; Lloret, A.; Borrás, C.; Pereda, J.; García-Sala, D.; Droy-Lefaix, MT.; Pallardó, FV.; Viña, J. Ginkgo biloba extract EGb 761 protects against mitochondrial aging in the brain and in the liver. Cell. Mol. Biol., 2002, 48, 685-692.
99. Van Dongen, MC.; van Rossum, E.; Kessels, AG.; Sielhorst, HJ.; Knipschild, PG. The efficacy of ginkgo for elderly people with dementia and age-associated memory impairment: new results of a randomized clinical trial. J. Am. Geriatr. Soc., 2000, 48, 1183-1194.
100. Le Bars, PL.; Kieser, M.; Itil, K.Z. A 26-week analysis of a doubleblind, placebo-controlled trial of the ginkgo biloba extract EGb 761 in dementia. Dement. Geriatr. Cogn. Disord., 2000, 11, 230-237.
101. Napryeyenko, O.; Sonnik, G.; Tartakovsky, I. Efficacy and tolerability of Ginkgo biloba exctract EGb 761 by type of dementia: analyses of a randomised controlled trial. J. Neurol. Sci., 2009, 283, 224-229.
102. Birks, J.; Grimley Evans, J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst. Rev., 2009, 1, CD003120.
103. Winblad, B. Piracetam: a review of pharmacological properties and clinical uses. CNS Drug Rev., 2005, 11, 169-182.
104. Pilch, H.; Müller, WE. Piracetam elevates muscarinic cholinergic receptor density in the frontal cortex of aged but not of young mice. Psychopharmacology, 1988, 94, 74-78.
105. Cohen, SA.; Müller, W.E. Effects of piracetam on N-methyl-Daspartate receptor properties in the aged mouse brain. Pharmacology, 1993, 47, 217-222.
106. Pepeu, G.; Spignoli, G. Nootropic drugs and brain cholinergic mechanisms. Prog. Neuro-Psychopharmacol. Biol. Psychiat., 1989, 13, S77-S88.
107. Villa, R.F.; Arnaboldi, R.; Gorini, A.; Geroldi, D. Action of piracetam and clonidine on different mitochondrial populations from hippocampus. Il Farmaco Ed. Sc., 1989, 44, 215-226.
108. Flicker, L.; Grimley Evans, G. Piracetam for dementia or cognitive impairment. Cochrane Database Syst. Rev., 2001, 2, CD001011.
109. Benzi, G.; Giuffrida, AM. Changes of synaptosomal energy metabolism induceed by hypoxia during aging. Neurochem. Res., 1987, 12, 149-157.
110. Villa, RF.; Turpeenoja, L.; Magrì, G.; Gorini, A.; Ragusa, N.; Giuffrida-Stella, AM. Effect of hypoxia on mitochondrial protein composition of cerebral cortex during aging. Neurochem. Res., 1991, 16, 821-826.
111. Inzitari, D.; Lamassa, M.; Pantoni, L. In: Vascular Cognitive Impairment: Preventable Dementia; Bowler, J.V.; Hachinski, V., Eds.; Oxford University Press: Oxford, 2003, pp. 277-292.
112. Baskys, A.; Hou, A.C. Vascular dementia: pharmacological treatment approaches and perspectives. Clin. Interv. Aging, 2007, 2, 327-335.
113. Tariot, P.N.; Farlow, M. R.; Grossberg, G.T.; Graham, S. M.; McDonald, S.; Gergel, I. For the Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil. A randomized controlled trial. JAMA, 2004, 291, 317-324.
114. Cacabelos, R.; Fernández-Novoa L.; Pichel, V.; Lombardi, V.; Kubota, Y.; Takeda, M. In: Pharmacogenomic Studies with a Combination Therapy in Alzheimer's Disease. Molecular Neurobiology of Alzheimer Disease and Related Disorders, Takeda, M.; Tanaka, T.; Cacabelos, R., Eds; Karger: Basel, 2004; pp. 94-107.
115. Cacabelos, R. Pharmacogenomics and therapeutic aspects in dementia. Eur. Arch. Psychiatry Clin. Neurosci., 2008, 258(Suppl 1), 28-47.
116. Miyamoto, N.; Tanaka, R.; Shimura, H.; Watanabe, T.; Mori, H.; Onodera, M.; Mochizuki, M.; Hattori, N.; Urabe, T. Phosphodiesterase III inhibition promotes differentiation and survival of oligodendrocytes progenitors and enhances recuperation of ischemic white matter lesions in the adult mammalian brain. J. Cerebr. Blood. Flow Metab., 2010, 30, 299-310.
117. Ekonomou, A., Ballard, C.G.; Pathmanaban, O.N.; Perry, R.H.; Perry, E.K.; Kalaria, R.N.; Mingel, S.L. Increased neural progenitors in vascular dementia. Neurobiol. Aging, 2010, [Epub ahead of print].
118. Benzi, G.; Moretti, A. Are reactive oxygen species involved in Alzheimer's disease? Neurobiol. Aging, 1995, 16, 661-674.
119. Bennett, S.; Grant, M.M.; Aldred, S. Oxidative stress in vascular dementia and Alzheimer's disease: a common pathology. J. Alzheimers Dis., 2009, 17, 245-257.
120. Villa, R.F.; Gorini, A. Pharmacology of lazaroids and brain energy metabolism: a review. Pharmacol. Rev., 1997, 49, 99-136.
121. Isaac, M.G.E.K.N.; Quinn, R.; Tabet, N. Vitamin E for Alzheimer's disease and mild cognitive impairment. Cochrane Database Suste. Rev., 2008, 3, CD002851.
122. Hachinski, V. Preventable senility: a call for action against the vascular dementias. Lancet, 1992, 340, 645-647.
123. Kloppenborg, R.P.; van den Berg, E.; Kappelle L.J.; Biessels, G.J. Diabetes and other vascular risk factors for dementia: which factor matter most? A systematic review. Eur. J. Pharmacol., 2008, 585, 97-108.
124. Piguet, O.; Garner, B. Vascular pharmacotherapy and dementia. Curr. Vasc. Pharmacol., 2010, 8, 44-50.
125. Jennings, J.R.; Muldoon, M.F.; Ryan, C.; Price, J.C.; Greer, P.; Sutton-Tyrrell, K.; van der Veen, F.M.; Meltzer, C.C. Reduced cerebral blood flow response and compensation among patients with untreated hypertension. Neurology, 2005, 64, 1358-1365.
126. Beason-Held, L.L.; Moghekar, A.; Zondermann, A.B.; Kraut, M.A.; Resnick, S.M. Longitudinal changes in cerebral blood flow in the older hypertensive brain. Stroke, 2007, 38, 1766-1773.
127. Hanon, O.; Seux, M.L.; Lenoir, H.; Rigaud, A.S.; Forette, F. Hypertension and dementia. Curr. Cardiol. Rep., 2003, 5, 435-440.
128. Paglieri, C.; Bisbocci, D.; Di Tullio, M.A; Tomassoni, D.; Amenta, F.; Veglio, F. Arterial hypertension: a cause of cognitive impairment and of vascular dementia. Clin. Exp. Hypertension, 2004, 26, 277-285.
129. Qiu, C.; Winblad, B.; Fratiglioni, L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol., 2005, 4, 487-499.
130. Birkenhager, W.H.; Staessen, J.S. Progress in cardiovascular diseases: cognitive function in essential hypertension. Prog. Cardiovasc. Dis., 2006, 49, 1-10.
131. Kennelly, S.P.; Lawlor, B.A.; Kenny, R.A. Blood pressure and the risk of dementia -A double edged sword. Ageing Res. Rev., 2009, 8, 61-70.
132. Yamada, M.; Kasagi, F.; Sasaki, H.; Masunari, N.; Mimori, Y.; Suzuki, G. Association between dementia and midlife risk factors: the Radiation Effects Research Foundation Adult Health Study. J. Am. Geriatr. Soc., 2003, 51, 410-414.
133. Whitmer, R.; Sidney, S.; Selby, J.; Claiborne Johnston, S.; Yaffe, K. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology, 2005, 64, 277-281.
134. Launer, L.J.; Ross, G.W.; Petrovitch, H.; Masaki, K.; Foley, D.; White, L.R.; Havlik, R.J. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol. Aging, 2000, 21, 49-55.
135. Steward, R.; Xue, Q-L.; Masaki, K.; Petrovitch, H.; Ross, G.W.; White, L.R.; Launer, L.J. Change in blood pressure and incident dementia. A 32-year prospective study. Hypertension, 2009, 54, 233-240.
136. Freitag, M.H.; Peila, R.; Masaki, K.; Petrovitch, H.; Ross, H.W.; White, L.R.; Launer, L.J. Midlife pulse pressure and incidence of dementia. The Honolulu-Asia Aging Study. Stroke, 2006, 37, 33-37.
137. Yoshitake, T.; Kiyohara, Y.; Kato, I.; Ohmura, T.; Iwamoto, H.; Nakayama, K.; Ohmori, S.; Nomiyama, K.; Kawano, H.; Ueda, K.; Sueishi, K.; Tsuneyoshi, M.; Fujishima, M. Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population: the Hisayama Study. Neurology, 1995, 45, 1161-1168.
138. Hayden, K.M.; Zandi, P.P.; Lyketsos, C.G.; Khachaturian, A.S.; Bastian, L.A.; Charoonruk, G.; Tschanz, J.A.T.; Norton, M.C.; Pieper, C.F.; Munger, R.G.; Breitner, J.C.S.; Welsh-Bohmer, K.A. For the Cache County Investigators. Vascular risk factors for incident Alzheimer disease and vascular dementia: The Cache County Study. Alzheimer Dis. Assoc. Disord., 2006, 20, 93-100.
139. Skoog, I.; Lernfelt, B.; Landahl, S.; Palmertz, B.; Andreasson, L.A.; Nilsson, L.; Persson, G.; Odén, A.; Svanborg, A. 15-year longitudinal study of blood pressure and dementia. Lancet, 1996, 347, 1141-1145.
140. Ruitenberg, A.; Skoog, I.; Ott, A.; Aevarsson, O.; Witteman, J.C.M.; Lernfelt, B.; van Harskamp, F.; Hofman, A.; Breteler, M.M.B. Blood pressure and risk of dementia: results from the Rotterdam study and the Gothenburg H-70 study. Dement. Geriatr. Cogn. Disord., 2001, 12, 33-39.
141. Verghese, J.; Lipton, R.B.; Hall, C.B.; Kuslanski, G.; Katz, M.J. Low blood pressure and the risk of dementia in very old individuals. Neurology, 2003, 61, 1667-1672.
142. Qiu, C.; von Strauss, E.; Fastbom, J.; Winblad, B.; Fratiglioni, L. Low blood pressure and risk of dementia in the Kungsholmen Project. Arch. Neurol., 2003, 60, 223-228.
143. Li, G.; Rhew, I.C.; Shofer, J.B.; Kukull, W.A.; Breitner, J.C.; Peskind, E.; Bowen, J.D.; McCormick, W.; Teri, L.; Crane, P.K.; Larson, E.B. Age-varying association between blood pressure and risk of dementia in those aged 65 and older: a community-based prospective cohort study. J. Am. Geriatr. Soc., 2007, 55, 1161-1167.
144. Wiseman, R.M.; Saxby, B.K.; Burton, E.J.; Barber, R.; Ford, G.A.; O'Brien, J.T. Hippocampal atrophy, whole brain volume, and white matter lesions in older hypertensive subjects. Neurology, 2004, 63, 1892-1897.
145. Den Heijer, T.; Skoog, I.; Oudkerk, M.; de Leeuw, F.E.; de Groot, J.C.; Hofman, A.; Breteler, M.M.B. Association between blood pressure levels over time and brain atrophy in the elderly. Neurobiol. Aging, 2003, 24, 307-313.
146. Dufouil, C.; de Kersaint-Gilly, A.; Besancon, V.; Levy, C.; Auffray, E.; Brunnereau, L.; Alpérovitch, A.; Tzourio, C. Longitudinal study of blood pressure and white matter hyperintensities. The EVA MRI cohort. Neurology, 2001, 56, 921-926.
147. Van Dijk, E.J.; Breteler, M.M.B.; Schmidt, R.; Berger, K.; Nilsson, L.G.; Oudkerk, M.; Pajak, A.; Sans, S.; de Ridder, M.; Dufouil, C.; Fuhrer, R.; Giampaoli, S.; Launer, L.J.; Hofman, A.; For the CASCADE Consortium The association between blood pressure, hypertension, and cerebral white matter lesions. Cardiovascular determinants of dementia study. Hypertension, 2004, 44, 625-630.
148. Manolio, T.A.; Olson, J.; Longstreth, W.T. Hypertension and cognitive function: pathophysiologic effects of hypertension on the brain. Curr. Hypertens. Rep., 2003, 5, 255-261.
149. Amenta, F.; Mignini, F.; Rabbia, F.; Tomassoni, D.; Veglio, F. Protective effect of anti-hypertensive treatment on cognitive function in essential hypertension: analysis of published clinical data. J. Neurol. Sci., 2002, 203-204, 147-151.
150. Birkenhager, W.H.; Forette, F.; Staessen, J.A. Dementia and antihypertensive treatment. Curr. Opin. Nephrol. Hypertens., 2004, 13, 225-230.
151. Feigin, V.; Ratnasabapathy, Y.; Anderson, C. Does blood pressure lowering treatment prevents dementia or cognitive decline in patients with cardiovascular and cerebral disease? J. Neurol. Sci., 2005, 229-230, 151-155.
152. Peters, R.; Beckett, N. Hypertension, dementia, and antihypertensive treatment: implications for the very elderly. Curr. Hypertens. Rep., 2009, 11, 277-282.
153. In't Veld, B.A.; Ruitenberg, A.; Hofman, A.; Stricker, B.H.Ch.; Breteler, M.M.B. Antihypertensive drugs and incidence of dementia: the Rotterdam Study. Neurobiol. Aging, 2001, 22, 407-412.
154. Peila, R.; White, L.R.; Masaki, K.; Petrovitch, H.; Launer, L.J. Reducing the risk of dementia. Efficacy of long-term treatment of hypertension. Stroke, 2006, 37, 1165-1170.
155. Forette, F.; Seux, M.L.; Staessen, J.A.; Thijs, L.; Birkenhager, W.H.; Babarskiene, M-R.; Babenau, S.; Bossini, A.; Gil-Extremera, B.; Girerd, X.; Laks, T.; Lilov, E.; Moisseyev, V.; Tuomilehto, J.; Vanhanen, H.; Webster, J.; Yodfat, Y.; Fagard, R.; On behalf of the Syst-Eur Investigators. Prevention of dementia in randomized double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet, 1998, 352, 1347-1351.
156. Forette, F.; Seux, M.L.; Staessen, J.A.; Thijs, L.; Babarskiene, M.R.; Babeanu, S.; Bossini, A.; Fagard, R.; Gil-Extremera, B.; Laks, T.; Kobalava, Z.; Sarti, C.; Tuomilehto, J.; Vanhanen, H.; Webster, J.; Yodfat, Y.; Birkenhager, W.H. For the Syst-Eur Investigators. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch. Intern. Med., 2002, 162, 2046-2052.
157. Hanon, O.; Forette, F. Prevention of dementia: lessons from SYSTEUR and PROGRESS. J. Neurol. Sci., 2004, 226, 71-74.
158. The PROGRESS Collaborative Group. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch. Int. Med., 2003, 163, 1069-1075.
159. Dufouil, C.; Chalmers, J.; Coskun, O.; Besançon, V.; Bousser, M.G.; Guillon, P.; MacMahon, S.; Mazoyer, B.; Neal, B.; Woodward, M.; Tzourio-Mazoyer, N.; Tzourio, C. Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke: the PROGRESS (Perindropil Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy. Circulation, 2005, 112, 1644-1650.
160. Peters, R.; Beckett, N.; Forette, F.; Tuomilehto, J.; Clarke, R.; Ritchie, C.; Waldman, A.; Walton, I.; Poulter, R.; Ma, S.; Comsa, M.; Burch, L.; Fletcher, A.; Bulpitt, C.; For the HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol., 2008, 7, 683-689.
161. Skoog, I.; Lithell, H.; Hansson, L.; Elmfeldt, D.; Hofman, A.; Olofsson, B.; Trenkwalder, P.; Zanchetti, A. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: study on cognition and Prognosis in the Elderly (SCOPE). Am. J. Hypertens., 2005, 18, 1052-1059.
162. Shah, K.; Qureshi, S.U.; Johnson, M.; Parikh, N.; Schulz, P.E.; Kunik, M.E. Does use of antihypertensive drugs affect the incidence or progression of dementia? A systematic review. Am. J. Geriatr. Pharmacother., 2009, 7, 250-261.
163. Lipsitz, L.A.; Gagnon, M.; Vyas, M.; Iloputaife, I.; Kiely, D.K.; Sorond, F.; Serrador, J.; Cheng, D.M.; Babikian, V.; Cupples, L.A. Antihypertensive therapy increases cerebral blood flow and carotid distensibility in hypertensive elderly subjects. Hypertension, 2005, 45, 216-221.
164. McGuiness, B.; Todd, S.; Passmore, P.; Bullock, R. Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database Syst. Rev., 2009, 4, CD004034.
165. De Leeuw, F.-E.; de Groot, J.C.; Oudkerk, M.; Witteman, J.C.M.; Hofman, J.; van Gijn, J.; Breteler, M.M.B. Hypertension and cerebral white matter lesions in a prospective cohort study. Brain, 2002, 125, 765-772.
166. Trompet, S.; Westendorp, R.G.J.; Kamper, A.M.; de Craen, A.J.M. Use of calcium antagonists and cognitive decline in old age. The Leiden 85-plus study. Neurobiol. Aging, 2008, 29, 306-308.
167. Hanon, O.; Pequignot, R.; Seux, M.L.; Lenoir, H.; Bune, A.; Rigaud, A.S.; Forette, F.; Girerd, X. Relationship between antihypertensive drug therapy and cognitive function in elderly hypertensive patients with memory complaints. J. Hypertens., 2006, 24, 2101-2107.
168. Khachaturian, Z.S. Calcium hypothesis of Alzheimer's disease and brain aging. Ann. NY Acad. Sci., 1994, 747, 1-11.
169. LaFerla, F.M. Calcium dyshomeostasis and intracellular signaling in Alzheimer's disease. Nat. Rev. Neurosci., 2002, 3, 862-872.
170. Amenta, F.; Di Tullio, M.A.; Tomassoni, D. Arterial hypertension and brain damage-evidence from animal models (review). Clin. Exp. Hypertens., 2003, 25, 359-380.
171. Gard, P.R. The role of angiotensin II in cognition and behaviour. Eur. J. Pharmacol., 2002, 438, 1-14.
172. Tedesco, M.A.; Ratti, G.; Mennella, S.; Manzo, G.; Grieco, M.; Rainone, A.C.; Iarussi, D.; Iacono, A. Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients. Am. J. Hypertens., 1999, 12, 1130-1134.
173. Fogari, R.; Mugellini, A.; Zoppi, A.; Derosa, G.; Pasotti, C.; Fogari, E.; Preti, P. Influence of losartan and atenolol on memory functionin very elderly hypertensive patients. J. Hum. Hypertens., 2003, 17, 781-785.
174. Rozzini, L.; Vicini Chilovi, B.; Bertoletti, E.; Conti, M.; Del Rio, I.; Trabucchi, M.; Padovani, A. Angiotensin converting enzyme (ACE) inhibitors modulate the rate of progression of amnestic mild cognitive impairment. Int. J. Geriatr. Psychiatry, 2006, 21, 550-555.
175. Hajjar, I.; Keown, M.; Frost, B. Antihypertensive agents for aging patients who are at risk for cognitive dysfunction. Curr. Hypertens. Rep., 2005, 7, 466-473.
176. Ohrui, T.; Tomita, N.; Sato-Nakagawa, T.; Matsui, T; Maruyama, M.; Niwa, K.; Arai, H.; Sasaki, H. Effects of brain-penetrating ACE inibitors on Alzheimer disease progression. Neurology, 2004, 63, 1324-1325.
177. Thöne-Reineke, C.; Steckelings, U.M.; Unger, T. Angiotensin receptor blockers and cerebral protection in stroke. J. Hypertens., 2006, 24(Suppl. 1), S115-S121.
178. Hanes, D. S.; Weir, M.R. Usefulness of ARBs and ACE inhibitors in the prevention of vascular dementia in the elderly. Am. J. Geriatr. Cardiol., 2007, 16, 175-182.
179. Fournier, A.; Oprisiu-Fournier, R.; Serot, J.-M.; Godefroy, O.; Achard, J.-M.; Faure, S.; Mazouz, H.; Temmar, M.; Albu, A.; Bordet, R.; Hanon, O.; Gueyffier, F.; Wang, J.; Black, S.; Sato, N. Prevention of dementia by antihypertensive drugs: how AT1- receptor-blockers and di-hydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors. Expert Rev. Neurother., 2009, 9, 1413-1431.
180. Inaba, S.; Iwai, M.; Furono, M.; Tomono, Y.; Kanno, H.; Senba, I.; Okayama, H.; Mogi, M.; Higaki, J.; Horiuchi, M. Continuous activation of renin-angiotensin systems impairs cognitive function in renin/angiotensin transgenic mice. Hypertension, 2009, 53(Part 2), 356-362.
181. Hirawa, N.; Uehara, Y.; Kawabata, Y.; Numabe, A.; Gomi, T.; Ikeda, T.; Suzuki, T.; Goto, A.; Toyo-oka, T.; Omata, M. Longterm inhibition of renin-angiotensin system sustains memory function in aged Dahl rats. Hypertension, 1999, 34, 496-502.
182. Sumbalová, Z.; Kucharská, J.; Kristek, F. Losartan improved respiratory function and coenzyme Q content in brain mitochondria of young spontaneously hypertensive rats. Cell Mol. Neurobiol. 2010, 30, 751-758.
183. Jenkins, T.A.; Chai, S.Y. Effect of chronic angiotensin converting enzyme inhibition on spatial memory and anxiety-like behaviours in rats. Neurobiol. Learn. Mem., 2007, 87, 218-224.
184. Panza, F.; D'Introno, A.; Colacicco, A.M.; Capurso, C.; Pichichero, G.; Capurso, S.A.; Capurso, A.; Solfrizzi, V. Lipid metabolism in cognitive decline and dementia. Brain Res. Rev., 2006, 51, 275-292.
185. Zuliani, G.; Blé, A.; Zanca, R.; Munari, M.R.; Zurlo, A.; Vavalle, C.; Atti, A.R.; Fellin, R. Lipoprotein profile in older patients with vascular dementia and Alzheimer's disease. BMC Geriatr., 2001, 1, 5.
186. Dufouil, C.; Richard, F.; Fiévet, N.; Dartigues, JF.; Ritchie, K.; Tzourio, C.; Amouyel, P.; Alpérovitch, A. APOE genotype, cholesterol level, lipid-lowering treatment, and dementia. The Three-City Study. Neurology, 2005, 64, 1531-1538.
187. Watanabe, T.; Koba, S.; Kawamura, M.; Itokawa, M.; Idei, T.; Nakagawa, Y.; Iguchi, T.; Katagiri, T. Small dense low-density lipoprotein and carotid atherosclerosis in relation to vascular dementia. Metabolism, 2004, 53, 476-482.
188. Solomon, A.; Kivipelto, M.; Wolozin, B.; Zhou, J.; Whitmer, R.A. Midlife serum cholesterol and increased risk of Alzheimer's and vascular dementia three decades later. Dement. Geriatr. Cogn. Disord., 2009, 28, 75-80.
189. Kalmijn, S.; Foley, D.; White, L.; Burchfiel, C.M., Curb, J.D.; Petrovitch, H.; Ross, G.W.; Havlik, R.J.; Launer, L.J. Metabolic cardiovascular syndrome and risk of dementia in Japanese- American elderly men. The Honolulu-Asia aging study. Arterioscler. Thromb. Vasc. Biol., 2000, 20, 2255-2260.
190. Steward, R.; White, L.R.; Xue, Q-L.; Launer, L.J. Twenty-six-year change in total cholesterol levels and incident dementia. Arch. Neurol., 2007, 64, 103-107.
191. Moroney, J.T.; Tang, M.X.; Berglund, L.; Small, S.; Merchant, C.; Bell, K.; Stern, Y.; Mayeux, R. Low-density lipoprotein cholesterol and the risk of dementia with stroke. JAMA, 1999, 281, 254-260.
192. Reitz, C.; Tang, M-X.; Luchsinger, J.; Mayeux, R. Relation of plasma lipids to Alzheimer disease and vascular dementia. Arch. Neurol., 2004, 61, 705-714.
193. Mielke, M.M.; Zandi, P.P.; Sjögren, M., Gustafson, D.; Ostling, S.; Steen, B.; Skoog, I. High total cholesterol levels in late life associated with reduced risk of dementia. Neurology, 2005, 64, 1689-1695.
194. Piguet, O.; Grayson, D.A., Creasey, H.; Bennett, H.P.; Brooks, W.S.; Waite, L.M.; Broe, G.A. Vascular risk factors, cognition and dementia incidence over 6 years in the Sydney Older Person study. Neuroepidemiology, 2003, 22, 165-171.
195. Urakami, K.; Wada-Isoe, K.; Wakutani, Y.; Ikeda, K.; Ji, Y.; Yamagata, K.; Kowa, H.; Okada, A.; Adachi, Y.; Nakashima, K. Lipoprotein(a) phenotypes in patients with vascular dementia. Dementia Geriatr. Cogn. Disord., 2000, 11, 135-138.
196. Emanuele, E.; Peros, E.; Tomaino, C.; Feudatari, E.; Bermardi, L.; Binetti, G.; Maletta, R.; Micieli, G.; Bruni, A.C.; Geroldi, D. Relation of apolipoprotein (a) size to Alzheimer's disease and vascular dementia. Dement. Geriatr. Cogn. Disord., 2004, 18, 189-196.
197. Spada, R.S.; Ferri, R.; Roccasalva, G.; Toscano, G.; Casentino, F.I.I. Lipoprotein(a), vascular dementia and Alzheimer's disease. Arch. Gerontol. Geriatr., 2001, Suppl. 7, 369-373.
198. Paciaroni, M.; Bogousslavsky, J. Statins and stroke prevention. Expert Rev. Cardiovasc. Ther., 2009, 7, 1231-1243.
199. Miida, T.; Takahashi, A.; Ikeuchi, T. Prevention of stroke and dementia by statin therapy: experimental and clinical evidence of their pleiotropic effects. Pharmacol. Ther., 2007, 113, 378-393.
200. Golomb, B.A.; Dimsdale, J.E.; White, H.L.; Ritchie, J.B.; Criqui, M.H. Reduction in blood pressure with statins: results from the UCSD Statin Study, a randomized trial. Arch. Intern. Med., 2008, 168, 721-727.
201. Kuller, L.H. Statins and dementia. Curr. Atheroscler. Rep., 2007, 9, 154-161.
202. Cramer, C.; Haan, M.N.; Galea, S.; Langa, KM.; Kalbfleisch, J.D. Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology, 2008, 71, 344-350.
203. Zhou, B.; Teramukai, S.; Fukushima, M. Prevention and treatment of dementia or Alzheimer's disease by statins: a meta-analysis. Dement. Geriatr. Cogn. Disord., 2007, 23, 194-201.
204. McGuiness, B.; Craig, D.; Bullock, R.; Passmore, P. Statins for the prevention of dementia. Cochrane Database Syst. Rev., 2009, 2, CD003160.
205. Rockwood, K. Epidemiological and clinical trials evidence about a preventive role for statins in Alzheimer's disease. Acta Neurol. Scand., 2006, 114(Suppl. 185), 71-77.
206. Suribhatla, S.; Dennis, M.S.; Potter, J.F. A study of statin use in the prevention of cognitive impairment of vascular origin in the UK. J. Neurol. Sci., 2005, 229-230, 147-150
207. Koladiya, R.U.; Jaggi, A.S.; Singh, N.; Sharma, BK. Ameliorative role of atorvastatin and pitavastatin in L-methionine induced vascular dementia in rats. BMC Pharmacol., 2008, 8, 14.
208. Almdal, T.; Scharling, H.; Jensen, J.S.; Vestergaard, H. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke and death: a population-based study of 13,000 men and women with 20 years of follow-up. Arch. Int. Med., 2004, 164, 1422-1426.
209. Biessels, G.J.; Staekenborg, S.; Brunner, E.; Brayne, C.; Scheltens, P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol., 2006, 5, 64-74.
210. Whitmer, R.A. Type 2 diabetes and risk of cogniitive impairment and dementia. Curr. Neurol. Neurosci. Rep., 2007, 7, 373-380.
211. Cukierman, T.; Gerstein, H.C.; Williamson, J.D. Cognitive decline and dementia in diabetes-systematic overview of prospective observational studies. Diabetologia, 2005, 48, 2460-2469.
212. Curb, J.D.; Rodriguez, B.L.; Abbott, R.D.; Petrovitch, H., Ross, G.W.; Masaki, K.H.; Foley, D.; Blanchette, P.L.; Harris, T.; Chen, R.; White, L.R. Longitudinal association of vascular and Alzheimer's dementias, diabetes, and glucose tolerance. Neurology, 1999, 52, 971-975.
213. Ott, A.; Stolk, R.P.; van Harskamp, F.; Pols, H.A.P.; Hofman, A.; Breteler, M.M.B. Diabetes mellitus and the risk of dementia - the Rotterdam Study. Neurology, 1999, 53, 1937-1942.
214. Akomolafe, A.; Beiser, A.; Meigs, J.B.; Au, R.; Green, R.C.; Farrer, L.A.; Wolf, P.A.; Seshadri, S. Diabetes mellitus and risk of developing Alzheimer disease. Arch. Neurol., 2006, 63, 1551-1555.
215. MacKnight, C.; Rockwood, K.; Awalt, E.; McDowell, I. Diabetes mellitus and the risk of dementia, Alzheimer's disease and vascular cognitive impairment in the Canadian Study of Health and Aging. Dement. Geriatr. Cogn. Disord., 2002, 14, 77-83.
216. Luchsinger, J.A.; Tang, M-X.; Stern, Y., Shea, S.; Mayeux, R. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am. J. Epidemiol., 2001, 154, 635-641.
217. Peila, R.; Rodriguez, B.L.; Launer, L.J. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies - The Honolulu-Asia Aging Study. Diabetes, 2002, 51, 1256-1262.
218. Xu, W.L.; Qiu, C.X.; Wahlin, A.; Winblad, B.; Fratiglioni, L. Diabetes mellitus and risk of dementia in the Kungsholmen project - A 6-year follow-up study. Neurology, 2004, 63, 1181-1186.
219. Hassing, L.B.; Johansson, B.; Nilsson, S.E.; Berg, S.; Pedersen, N.L.; Gatz, M.; McCleearn, G. Diabetes mellitus is a risk factor for vascular dementia, but not for Alzheimer's disease: a populationbased study of the oldest old. Int. Psychogeriatr., 2002, 14, 239-248.
220. Xu, W.; Qiu, C.; Gatz, M.; Pedersen, N.L.; Johansson, B.; Fratiglioni, L. Mid- and late-life diabetes in relation to the risk of dementia: a population-based twin study. Diabetes, 2009, 58, 71-77.
221. Logroscino, G.; Kang, J.H.; Grodstein, F. Prospective study of type 2 diabetes and cognitive decline in women aged 70-81 years. BMJ, 2004, 328, 548-551.
222. Abbatecola, A.M.; Rizzo, M.R.; Barbieri, M.; Grella, R.; Arciello, A.; Laieta, M.T.; Acampora, R.; Passariello, N.; Cacciapuoti, F.; Paolisso, G. Postprandial plasma glucose excursion and cognitive functioning in aged type 2 diabetes. Neurology, 2006, 67, 235-240.
223. Ryan, C.M.; Freed, M.I.; Rood, J.A.; Cobitz, A.R.; Waterhouse, B.R.; Strachan, M.W.J. Improving metabolic control leads to better working memory in adults with Type 2 diabetes. Diabetes Care, 2006, 29, 345-351.
224. Risner, M.E.; Saunders, A.M.; Altman, J.F.B.; Ormandy, G.C., Craft, S.; Foley, I.M.; Zvartau-Hind, M.E.; Hosford, D.A.; Roses, A.D. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J., 2006, 6, 246-254.
225. Landreth, G. PPARγ agonists as new therapeutic agents for the treatment of Alzheimer's disease. Exp. Neurol., 2006, 199, 245-248.
226. Whitmer, R.A.; Karter, A.J.; Yaffe, K.; Quesenberry Jr. C.P.; Selby, J.V. Hypoglycemic episodes and risk of dementia in older patients with Type 2 diabetes mellitus. JAMA, 2009, 301, 1565-1572.
227. The ONTARGET Investigations. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med., 2008, 358, 1547-1559.
228. Kario, K.; Ishikawa, J.; Hoshide, S.; Matsui, Y.; Morinari, M.; Educhi, K.; Ishikawa, S.; Shimada, K. Diabetic brain damage in hypertension: role of renin-angiotensin system. Hypertension, 2005, 45, 887-893.
229. Rossi, G.P. Losartan metabolite EXP3179: an AT1-receptorindependent treatment strategy for patients with the metabolic syndrome? Hypertension, 2009, 54, 710-712.
230. Manschot, S.M.; Biessels, G.J., Cameron, N.E.; Cotter, M.A.; Kamal, A.; Kappelle, L.J.; Gispen, W.H. Angiotensin converting enzyme inhibition partially prevents deficits in water maze performance, hippocampal synaptic plasticity and cerebral blood flow in streptozotocin-diabetic rats. Brain Res., 2003, 966, 274-282.
231. Tsukuda, K.; Mogi, M.; Li, J-M.; Iwanami, J.; Min, L-J.; Sakata, A.; Fujita, T.; Iwai, M.; Horiuchi, M. Diabetes-associated cognitive impairment is improved by a calcium channel blocker, nifedipine. Hypertension, 2008, 51(Part 2), 528-533.
232. Gustafson, D. Adiposity indices and dementia. Lancet Neurol., 2006, 5, 713-720.
233. Gorospe, E.C.; Dave, J.K. The risk of dementia with increased body mass. Age Ageing, 2007, 36, 23-29.
234. Whitmer, R.A.; Gunderson, E.P.; Quesenberry Jr, C.P.; Zhou, J.; Yaffe, K. Body mass index and risk of Alzheimer disease and vascular dementia. Curr. Alzheimer Res., 2007, 4, 103-109.
235. Rosengren, A.; Skoog, I.; Gustafson, D.; Wilhelmsen, L. Body mass index, other cardiovascular risk factors, and hospitalization for dementia. Arch. Int. Med., 2005, 165, 321-326.
236. Luchsinger, J.A.; Patel, B.; Tang, M-X.; Schupf, N.; Mayeux, R. Measures of adiposity and dementia risk in elderly persons. Arch. Neurol., 2007, 64, 392-398.
237. Fitztpatrick, A.L.; Kuller, L.H.; Lopez, O.L.; Diehr, P.; O'Meara, E.S.; Longstreth W.T. Jr.; Luchsinger, J.A. Midlife and late-life obesity and the risk of dementia. Arch. Neurol., 2009, 66, 336-342.
238. Knopman, D.S.; Edland, S.D.; Cha, R.H.; Petersen, R.C.; Rocca, W.A. Incident dementia in women is preceded by weight loss by at least a decade. Neurology, 2007, 69, 739-746.
239. Steward, R.; Masaki, K.; Xue, Q-L.; Peila, R.; Petrovitch, H.; White, LR.; Launer, L.J. A 32-year prospective study of change in body weight and incident dementia. Arch. Neurol., 2005, 62, 55-60.
240. Kivipelto, M.; Ngandu, T.; Fratiglioni, L.; Viitanen, M.; Kåreholt, I.; Winblad, B.; Helkala, E-L.; Tuomilehto, J.; Soinenen, H.; Nissinen, A. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch. Neurol., 2005, 62, 1556-1560.
241. Whitmer, R.A.; Gustafson, D.R.; Barrett-Connor, E.; Haan, M.N.; Gunderson, E.P.; Yaffe, K. Central obesity and increased risk of dementia more than three decades later. Neurology, 2008, 71, 1057-1064.
242. Gustafson, D.; Lissner, L.; Bengtsson, C.; Björkelund, C.; Skoog, I. A 24-year follow-up of body mass index and cerebral atrophy. Neurology, 2004, 63, 1876-1881.
243. Winocur, G.; Greenwood, C.E. Studies of the effects of high fat diets on cognitive function in a rat model. Neurobiol. Aging, 2005, 26S, S46-S49.
244. Winocur, G.; Greenwood, C.E.; Piroli, G.C.; Grillo, C.A.; Reznikov, L.R.; Reagan, L.P.; McEwen, B.S. Memory impairment in obese Zucker rats: an investigation of cognitive function in an animal model of insulin resistance and obesity. Behav. Neurosci., 2005, 119, 1389-1395.
245. Wesnes, KA.; Garratt, C.; Wickens, M.; Gudgeon, A.; Oliver, S. Effects of sibutramine alone and with alcohol on cognitive function in healthy volunteers. Br. J. Clin. Pharmacol., 2000, 49, 110-117.
246. Esbenshade, T.A.; Fox, G.B.; Cowart, M.D. Histamine H3 receptor antagonists: preclinical promise for treating obesity and cognitive disorders. Mol. Interv., 2006, 6, 77-88.
247. Heal, D.J.; Smith, S.L.; Fisas, A.; Codony, X.; Buschmann, H. Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders. Pharmacol. Ther., 2008, 117, 207-231.
248. Peila, R.; Launer, L.J. Inflammation and dementia: epidemiologic evidence. Acta Neurol. Scand., 2006, 114(Suppl. 185), 102-106.
249. Schmidt, R.; Schmidt, H.; Curb, J.D.; Masaki, K.; White, L.R.; Launer L.J. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann. Neurol., 2002, 52, 168-174.
250. Enghelhart, M.J.; Geerlings, M.I.; Meijer, J.; Kiliaan, A.; Ruitenberg, A.; van Swieten, J.C.; Stijnen, T.; Hofman, A.; Witteman, J.C.M.; Breteler, M.M.B. Inflammatory proteins in plasma and the risk of dementia. Arch. Neurol., 2004, 61, 668-672.
251. Ravaglia, G.; Forti, P.; Maioli, F.; Chiappelli, M.; Montesi, F.; Tumini, E.; Mariani, E.; Licastro, F.; Patterson, C. Blood inflammatory markers and risk of dementia: the Conselice Study of Brain Aging. Neurobiol. Aging, 2007, 28, 1810-1820.
252. Van Oijen, M.; van der Meer, I.M.; Hofman, A.; Witteman, J.C.M.; Koudstaal, P.J.; Breteler, M.M.B. Lipoprotein-associated phospholipase A2 is associated with risk of dementia. Ann. Neurol., 2006, 59, 139-144.
253. Van Oijen, M.; Witteman, J.C.; Hofman, A.; Koudstaal, P.J.; Breteler, M.M.B. Fibrinogen is associated with an increased risk of Alzheimer disease and vascular dementia. Stroke, 2005, 36, 2637-2641.
254. Lee, S.C.; Liu, W.; Dickson, D.W.; Brosnan, C.F.; Barman, J.W. Cytokine production by human fetal microglia and astrocytes. Differential induction by lipopolysaccharide and IL-1b. J. Immunol. 1993, 150, 2659-2667.
255. Wada-Isoe, K.; Wakutani, Y.; Urakami, K.; Nakashima, K. Elevated interleukin-6 leveles in cerebrospinal fluid of vascular dementia patients. Acta Neurol. Scand., 2004, 110, 124-127.
256. Tarkowski, E.; Liljeroth, A-M.; Minthon, L.; Tarkowski, A.; Wallin, A.; Blennow, K. Cerebral pattern of pro- and anti-inflammatory cytokines in dementias. Brain Res. Bull., 2003, 61, 255-260.
257. De Simoni, M.G.; Sironi, M.; De Luigi, A.; Manfridi, A.; Mantovani, A.; Grezzi, P. Intracerebroventricular injection of interleukin 1 induces high circulating levels of interleukin 6. J. Exp. Med., 1990, 171, 1773-1778.
258. Mulugeta, E.; Molina-Holgado, F.; Elliott, M.S.; Hortobagyi, T.; Perry, R.; Kalaria, R.N.; Ballard, C.G.; Francis, P.T. Inflammatory mediators in the frontal lobe of patients with mixed and vascular dementia. Dement. Geriatr. Cogn. Disord., 2008, 25, 278-286.
259. Rozzini, R.; Ferrucci, L.; Losonczy, K.; Havlik, R.J.; Guralnik, J.M. Protective effect of chronic NSAID use on cognitive decline in older persons. J. Am. Geriatr. Soc., 1996, 44, 1025-1029.
260. Kang, J.H.; Grodstein, F. Regular use of nonsteroidal anti-inflammatory drugs and cognitive function in aging women. Neurology, 2003, 60, 1591-1597.
261. Hanlon, J.T.Y.; Schmader, K.E.; Landerman, L.R.; Horner, R.D.; Fillenbaum, G.G.; Pieper, CF.; Wall, W.E. Jr.; Koronkowski, M.J.; Cohen, H.J. Relation of prescription nonsteroidal anti-inflammatory drug use to cognitive function among community-dwelling elderly. Ann. Epidemiol., 1997, 7, 87-94.
262. Hayden, K.M.; Zandi, P.P.; Khachaturian, A.S.; Szekely, C.A.; Fotuhi, M.; Norton, M.C.; Tschanz, J.T.; Pieper, C.F.; Corcoran, C.; Lyketsos, C.G.; Breitner, J.C.S.; Welsh-Bohmer, K.A. Does NSAID use modify cognitive trajectories in the elderly? The Cache County Study. Neurology, 2007, 69, 275-282.
263. Szekely, CA.; Breitner, J.C.; Fitzpatrick, A.L.; Rea, T.D.; Psaty, B.M.; Kuller, L.H.; Zandi, P.P. NSAID use and dementia risk in the Cardiovascular Study: role of APOE and NSAID type. Neurology, 2008, 70, 17-24.
264. Andersohn, F.; Suissa, S.; Garbe, E. Use of first- and secondcyclooxygenase- 2-selective nonsteroidal anti-inflammatory drugs and risk of acute myocardial infarction. Circulation, 2006, 113, 1950-1957.
265. Andersohn, F.; Schade, R.; Suissa, S.; Garbe, E. Cyclooxygenase nonsteroidal antiinflammatory drugs and the risk of ischemic stroke. Stroke, 2006, 37, 1725-1730.
266. Salpeter, S.R.; Gregor, P., Ormiston, T.M.; Whitlock, R.; Raina, P.; Thabane, L.; Topol, E.J. Meta-analysis: cardiovascular events associated with nonsteroidal anti-inflammatory drugs. Am. J. Med., 2006, 119, 552-559.
267. Jonker, C.; Comijs, H.C.; Smit, J.H. Does aspirin or other NSAIDs reduce the risk of cognitive decline in elderly persons? Results from a population-based study. Neurobiol. Aging, 2003, 24, 583-588.
268. Richards, M.; Meade, T.W.; Pearl, S.; Brennan, P.J.; Mann, A.H. Is there any evidence for a protective effect of antithrombotic medication on cognitive function in men at risk of cardiovascular disease? Some preliminary findings. J. Neurol. Neurosurg. Psychiat., 1997, 62, 269-272.
269. Kang, J.H.; Cook, N.; Manson, J.; Buring, J.E.; Grodstein, F. Low dose aspirin and cognitive function in the women's health study cognitive cohort. BMJ, 2007, 334, 987.
270. Price, J.F.; Steward, M.C.; Deary, I.J.; Murray, G.D.; Sandercock, P.; Butcher, I.; Fowkes, F.G.R. On behalf of AAA Trialists. Low dose aspirin and cognitive function in middle aged to elderly adults: randomised controlled trial. BMJ, 2008, 337, 198.
271. Rastas, S.; Pirttilä, T.; Mattila, K.; Verkkoniemi, A.; Juva, K.; Niinistö, L.; Länsimies, E.; Sulkava, R. Vascular risk factors and dementia in the general population aged > 85 years. Prospective population-based study. Neurobiol. Aging, 2010, 31, 1-7.
272. Yaffe, K. Metabolic syndrome and cognitive disorders. Is the sum greater than its parts? Alzheimer Dis. Assoc. Disord., 2007, 21, 167-171.
273. Ford, E.S.; Giles, W.H.; Dietz, W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA, 2002, 287, 356-359.
274. Ford, E.S.; Li, C.; Zhao, G.; Pearson, W.S.; Mokdah, A.H. Prevalence of the metabolic syndrome among U.S. adolescents using the definition from the International Diabetes Federation. Diabetes Care, 2008, 31, 587-589.
275. Rodriguez-Colon, S.M.; Mo, J.; Duan, Y.; Liu, J.; Caulfield, J.E.; Jin, X.; Liao, D. Metabolic syndrome clusters and the risk of incident stroke. The Atherosclerosis risk in communities (ARIC) study. Stroke, 2009, 40, 200-205.
276. Roberts, K.C.; Sindhu, K.K. Oxidative stress and metabolic syndrome. Life Sci., 2009, 84, 705-712.
277. Yaffe, K. Metabolic Syndrome and cognitive decline. Curr. Alzheimer Res., 2007, 4, 123-126.
278. Van den Berg, E.; Biessels, G.J.; de Craen, A.J.M.; Gussekloo, J.; Westendorp, R.G.J. The metabolic syndrome is associated with decelerated cognitive decline in the oldest old. Neurology, 2007, 69, 979-985.
279. Raffaitin, C.; Gin, H.; Empana, J-P.; Helmer, C.; Berr, C.; Tzourio, C.; Portet, F.; Dartigues, J-F.; Alperovitch, A.; Barbeger-Gateau, P. Metabolic Syndrome and risk for incident Alzheimer's disease or vascular dementia: The Three-City Study. Diabetes Care, 2009, 32, 169-174.
280. Solfrizzi, V.; Scafato, E.; Capurso, C.; D'Introno, A.; Colacicco, A.M.; Frisardi, V.; Vendemiale, G.; Baldereschi, M.; Crepaldi, G.; Di Carlo, A.; Galluzzo, L.; Gandin, C.; Inzitari, D.; Maggi, S.; Capurso, A.; Panza, F. For the Italian Longitudinal Study on Ageing Working Group. J. Neurol. Neurosurg. Psychiatry, 2010, 81, 433-440.
281. Muller, M.; Tang, M-X.; Schupf, N.; Manly, J.J.; Mayeux, R.; Luchsinger, J.A. Metabolic syndrome and dementia risk in a multiethnic eledrly cohort. Dement. Geriatr. Cogn. Disord., 2007, 24, 185-192.
282. Scott, R.; O'Brien, R.; Fulcher, G.; Pardy, C.; D'Emden, M.; Tse, D.; Taskinen, M-R.; Enholm, C.; Keeck, A. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome. Diabetes Care, 2009, 32, 493-498.
283. Prasad, A.; Quyyumi, A.A. Renin-angiotensin system and angiotensin receptor blockers in the metabolic syndrome. Circulation, 2004, 110, 1507-1512.
284. Mogi, M.; Horiuchi, M. Effects of angiotensin II receptor blockers on dementia. Hypertens. Res., 2009, 32, 738-740.
285. Mogi, M.; Tsukuda, K.; Li, J-M.; Iwanami, J.; Min, L-J.; Sakata, A.; Fujita, T.; Iwai, M.; Horiuchi, M. Inhibition of cognitive decline in mice fed a high-salt and cholesterol diet by the angiotensin receptor blocker, olmesartan. Neuropharmacology, 2007, 53, 899-905.
286. Matsuzaki, G.; Ishizaka, N.; Furuta, K.; Hongo, M.; Saito, K.; Sakurai, R.; Koike, K.; Nagai, R. Comparison of vasculoprotective effects of benidepine and losartan in a rat model of metabolic syndrome. Eur. J. Pharmacol., 2008, 587, 237-242.
287. Ortlepp, J.R.; Breuer, J.; Eitner, F.; Kluge, K.; Kluge, R.; Floege, J.; Hollweg, G.; Hanrath, P.; Joost, H-G. Inhibition of the reninangiotensin system ameliorates genetically determined hyperinsulinemia. Eur. J. Pharmacol., 2002, 436, 145-150.
288. Muñoz, M.C.; Giani, J.F.; Dominici, F.P.; Turyn, D.; Tobbli, J.E. Long-term treatment with an angiotensin II receptor blocker decreases adipocyte size and improved insulin signaling in obese Zucker rats. J. Hypertens., 2009, 27, 2409-2420.
289. Fratiglioni, L.; Paillard-Borg, S.; Winblad, B. An active and socially integrated lifestyle in late life might protect against dementia. Lancet Neurol., 2004, 3, 343-353.
290. Grodstein, F. Cardiovascular risk factors and cognitive function. Alzheimer Dement., 2007, 3, S16-S22.
291. Rojas-Fernandez, C.H.; Moorhouse, P. Current concepts in vascular cognitive impairment and pharmacotherapy implications. Ann. Pharmacother., 2009, 43, 1310-1323.
292. Richard, E.; den Heuvel, E.V.; Mollvan Charante, E.P.; Achthoven, L.; Vermeulen, M.; Bindels, P.J.; van Gool, W.A. Prevention of dementia by intensive vascular care (preDIVA): a clusterrandomized trial in progress. Alzheimer Dis. Assoc. Disord., 2009, 23, 198-204.
293. Hakim, A.M. Vascular disease: the tsunami of health care. Stroke, 2007, 38, 3296-3301.